Hundreds of nurses gathered outside a Nashville courthouse to protest RaDonda Vaught’s prosecution for a medical mistake, and cheered when her probation sentence was announced.
Travel nurse contracts that were plentiful and paid the temporary nurses far more than hospital staff nurses are vanishing. Hospitals nationwide are turning their energies to recruiting full-time people.
A Massachusetts health care cost watchdog agency helped block plans of the state’s largest hospital system to expand into the suburbs. Now, other states are looking at whether Massachusetts’ decade-old model of controlling health costs is worth emulating.
Even the savviest Medicare drug plan shoppers can get a shock when they fill prescriptions: That great deal on medications is no bargain after prices go up.
After a Tennessee nurse killed a patient because of a drug error, the companies behind hospital medication cabinets said they’d make the devices safer. But did they?
Dying malls have turned out to be good places to care for the living. During the pandemic, mall-to-medicine transitions accelerated, with at least 10 health systems moving in where retail has moved out.
Colorado is requiring insurers that offer public option plans to collect demographic data on health providers, including race and sexual orientation. The aim is to connect patients with the right provider, but providers are worried about their privacy.
Federal funding that paid for covid testing, treatment, and vaccines for uninsured people has run out. While some states struggle to make up the difference, California is relying on other state and local programs to continue free testing.
As Google joins Apple in adding heart rhythm sensors to wearable devices, and millions of people gain access to alerts that flag when their hearts might have skipped a beat, cardiologists are wondering what to do with all the information.
The hydroxychloroquine and ivermectin fiascoes have soured many doctors on repurposing drugs for covid. A few inexpensive old drugs may be as good as some of the new antivirals, but they face complex obstacles to get to patients.